<DOC>
	<DOC>NCT00608296</DOC>
	<brief_summary>The purpose of the research is to study brain structure, function and chemistry of patients with bipolar disorder who are receiving quetiapine or lithium, in order to better understand who benefits from treatment and why they respond to medications.</brief_summary>
	<brief_title>Functional and Neurochemical Brain Changes Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Inclusion Criteria Depressed bipolar patients (N=100; 1520 patients/year): 1. Patients will meet DSMIV criteria for type I bipolar disorder, depressed, as determined by structured interview and bestestimate diagnostic procedures.138 2. Patient has experienced a maximum of three documented affective episodes. 3. Patient has been off medications for one week prior to study enrollment. 4. Patient has a Hamilton Depression Rating Scale (HDRS) total score ≥20 5. Patient is between the ages of 12 and 35 years. Exclusion criteria: All subjects will be excluded from participation for the following reasons: 1. Any chemical use disorder within 3 months. 2. Any history of significant suicidality that would place the patient at risk to participate in this protocol. 3. Current score ≥3 on item 3 of the HDRS17 (Suicide Item) 4. Any medical or neurological disorder that could influence fMRI results. 5. A history of mental retardation or an estimated IQ total score &lt;85. 6. An MRI scan is contraindicated in the subject for any reason. 7. The patient lives &gt;100 miles from the University of Cincinnati or cannot attend followup visits. 8. Meets DSMIV criteria for a bipolar mixed episode</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>